Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 116

Sort by

Sort Order Select

Journal Articles

Novel agents and immune invasion in Hodgkin lymphoma

Reid W. Merryman, Ann LaCasce

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 243–248.

https://doi.org/10.1182/hematology.2019000029

Published: 2019

Journal Articles

Opportunities for immunotherapy in childhood acute myeloid leukemia

Adam J. Lamble, Sarah K. Tasian

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 218–225.

https://doi.org/10.1182/hematology.2019000357

Published: 2019

Journal Articles

Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment

Scott F. Huntington

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 252–259.

https://doi.org/10.1182/hematology.2019000030

Published: 2019

Journal Articles

Indolent lymphomas: pushing the pace with novel agents

Caron A. Jacobson

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 279–286.

https://doi.org/10.1182/hematology.2019000032

Published: 2019

Journal Articles

Myeloma: next generation immunotherapy

Adam D. Cohen

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 266–272.

https://doi.org/10.1182/hematology.2019000068

Published: 2019

Journal Articles

CAR T-cell therapy: is it prime time in myeloma?

Surbhi Sidana, Nina Shah

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 260–265.

https://doi.org/10.1182/hematology.2019000370

Published: 2019

Journal Articles

Where does transplant fit in the age of targeted therapies?

Victor A. Chow, Ajay K. Gopal

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 287–293.

https://doi.org/10.1182/hematology.2019000033

Published: 2019

Journal Articles

Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?

Lori Muffly, Emily Curran

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 17–23.

https://doi.org/10.1182/hematology.2019000009

Published: 2019

Journal Articles

Microbiota modification in hematology: still at the bench or ready for the bedside?

Christopher J. Severyn, Ryan Brewster, Tessa M. Andermann

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 303–314.

https://doi.org/10.1182/hematology.2019000365

Published: 2019

Journal Articles

Management of older Hodgkin lymphoma patients

Andrew M. Evens, Jordan Carter, Kah Poh Loh, Kevin A. David

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 233–242.

https://doi.org/10.1182/hematology.2019000028

Published: 2019

Journal Articles

Moving immunotherapy into the front line in ALL

Amanda Winters, Lia Gore

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 209–217.

https://doi.org/10.1182/hematology.2019000017

Published: 2019

Journal Articles

Integrating patient-centered factors in the risk assessment of MDS

Rena J. Buckstein

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 373–380.

https://doi.org/10.1182/hematology.2019000041

Published: 2019

Journal Articles

Meeting the needs of CML patients in resource-poor countries

Hemant Malhotra, Jerald Radich, Pat Garcia-Gonzalez

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 433–442.

https://doi.org/10.1182/hematology.2019000050

Published: 2019

Journal Articles

Sequencing of therapies in relapsed follicular lymphoma

Loretta J. Nastoupil, Christopher R. Flowers, John P. Leonard

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 189–193.

https://doi.org/10.1182/asheducation-2018.1.189

Published: 2018

Journal Articles

Novel therapies for relapsed/refractory aggressive lymphomas

Jonathon B. Cohen

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 75–82.

https://doi.org/10.1182/asheducation-2018.1.75

Published: 2018

Journal Articles

Using genomics to define pediatric blood cancers and inform practice

Rachel E. Rau, Mignon L. Loh

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 286–300.

https://doi.org/10.1182/asheducation-2018.1.286

Published: 2018

Journal Articles

Novel immunotherapy approaches to follicular lymphoma

Christopher R. Flowers, John P. Leonard, Loretta J. Nastoupil

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 194–199.

https://doi.org/10.1182/asheducation-2018.1.194

Published: 2018

Journal Articles

Risk-adapted therapy for advanced-stage Hodgkin lymphoma

Michael A. Spinner, Ranjana H. Advani

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 200–206.

https://doi.org/10.1182/asheducation-2018.1.200

Published: 2018

Journal Articles

New drugs for acute myeloid leukemia inspired by genomics and when to use them

Daniel A. Pollyea

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 45–50.

https://doi.org/10.1182/asheducation-2018.1.45

Published: 2018

Journal Articles

Hypereosinophilic syndrome: approach to treatment in the era of precision medicine

Amy Klion

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 326–331.

https://doi.org/10.1182/asheducation-2018.1.326

Published: 2018

NARROW

Novel agents and immune invasion in Hodgkin lymphoma

Opportunities for immunotherapy in childhood acute myeloid leukemia

Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment

Indolent lymphomas: pushing the pace with novel agents

Myeloma: next generation immunotherapy

CAR T-cell therapy: is it prime time in myeloma?

Where does transplant fit in the age of targeted therapies?

Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?

Microbiota modification in hematology: still at the bench or ready for the bedside?

Management of older Hodgkin lymphoma patients

Moving immunotherapy into the front line in ALL

Integrating patient-centered factors in the risk assessment of MDS

Meeting the needs of CML patients in resource-poor countries

Sequencing of therapies in relapsed follicular lymphoma

Novel therapies for relapsed/refractory aggressive lymphomas

Using genomics to define pediatric blood cancers and inform practice

Novel immunotherapy approaches to follicular lymphoma

Risk-adapted therapy for advanced-stage Hodgkin lymphoma

New drugs for acute myeloid leukemia inspired by genomics and when to use them

Hypereosinophilic syndrome: approach to treatment in the era of precision medicine

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only